Anavex Announces First Entire Clinical Gene Pathway Data of ANAVEX2-73 from AVATAR Study in Patients with Rett Syndrome - Seite 2

ANAVEX2-73 Treatment-enriched Pathways
Pathway Name	Category	p-value
Oxidative phosphorylation	Energy Metabolism	2.84E-04
Valine leucine and isoleucine degradation	Metabolism	6.85E-04
Adipogenesis	Energy Metabolism	1.48E-03
Fatty acid degradation	Energy Metabolism	5.52E-03
Amino acid metabolism	Metabolism	7.14E-03
Cysteine and methionine metabolism	Metabolism	8.41E-03
Acyl chain remodeling of phosphatidylserine	Metabolism	1.43E-02
Mitochondrial protein import	Energy Metabolism	1.71E-02
α-Linolenic acid metabolism	Metabolism	1.83E-02
PPAR-α pathway	Signaling	1.98E-02
Acyl chain remodeling of phosphatidylethanolamine	Metabolism	2.43E-02
TGF-β signaling pathway	Signaling	2.49E-02
Deubiquitination	Metabolism	2.99E-02
NOD1/2 signaling pathway	Signaling	3.09E-02
Fatty acid β-oxidation	Energy Metabolism	3.26E-02
Detoxification of reactive oxygen species	Metabolism	3.26E-02
N-glycan trimming in ER and calnexin/calreticulin cycle	Metabolism	3.44E-02
miRNAs involvement in the immune response in sepsis	Transcription / Translation	3.81E-02
RHOV GTPase cycle	Signaling	3.81E-02
Formation of xylulose-5-phosphate	Metabolism	4.11E-02
NR1H2 and NR1H3 regulate gene expression linked to gluconeogenesis	Transcription / Translation	4.11E-02
RHOU GTPase cycle	Signaling	4.20E-02
Fatty acid metabolism	Energy Metabolism	4.36E-02
Nucleotide-binding oligomerization domain (NOD) pathway	Transcription / Translation	4.60E-02
Protein localization	Membrane Trafficking	4.89E-02
Glycerophospholipid metabolism	Metabolism	4.89E-02